Clinical trials: Body Weight Control
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
- Conditions
- Obesity, Overweight, Chronic Low Back Pain (CLBP)
- Trial name
- TRIUMPH-7 (NCT07035093)
- Testing
- Retatrutide
- Where
- 40 sites in United States, Argentina and 2 more
- Volunteers
- 586 people
- Sponsor
- Eli Lilly and Company
Obesity, Nonalcoholic Steatohepatitis
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects.
- Trial name
- NCT04561245
- Testing
- ALT-801
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Overweight , Obesity
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.
- Trial name
- NCT07230119
- Testing
- Zovaglutide dose 1, Zovaglutide dose 2
- Where
- 45 sites in China
- Volunteers
- 755 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Cachexia, Pancreatic Neoplasms
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.
- Trial name
- NCT00060502
- Testing
- Infliximab; Gemcitabine
- Volunteers
- 73 people
- Sponsor
- Centocor, Inc.
Nausea and Vomiting, Obesity
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one…
- Trial name
- NCT07446439
- Testing
- Tradipitant
- Where
- 10 sites in United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Obesity and Overweight
A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health
This study aims to evaluate the impact of a specific oral postbiotic supplement on metabolic health in overweight adults.
- Trial name
- NCT06911073
- Testing
- Postbiotic
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- ResBiotic Nutrition, Inc.
Weight Loss
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- NCT07104383
- Testing
- VK2735
- Where
- 127 sites in United States, Puerto Rico
- Volunteers
- 1,100 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity
Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects
The purpose of this study is to evaluate the safety, tolerability and effect on body weight and other obesity-related factors of different doses of BMS-830216, compared to placebo.
- Trial name
- NCT00909766
- Testing
- BMS-830216
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Obesity
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Trial name
- NCT07458269
- Testing
- Ribupatide
- Where
- 35 sites in United States
- Volunteers
- 264 people
- Sponsor
- Kailera
Obesity
Study to Evaluate ARD-101 in Adults With Obesity
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.
- Trial name
- NCT05121441
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aardvark Therapeutics, Inc.
Diabetes Type 2, Diabetes
Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes
This is a prospective, multicenter, randomized, double-blind, sham-controlled, adaptive study evaluating the pulsENDO system in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering…
- Conditions
- Diabetes Type 2, Diabetes, Diabetes (DM), Weight Change
- Trial name
- pulsENDO (NCT07768631)
- Testing
- pulsENDO Therapy
- Volunteers
- 320 people
- Sponsor
- Endogenex, Inc.
Obesity and Overweight
A Randomized Controlled Trial Comparing the Efficacy of Commercial Weight Management Programs
The study compares the effectiveness of three commercial weight management programs. The primary outcome is absolute and percentage weight change at 12-weeks.
- Trial name
- NCT06972277
- Testing
- Commercial weight management program
- Where
- United States
- Volunteers
- 459 people
- Sponsor
- WW International Inc
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387269
- Testing
- Anamorelin HCl
- Where
- 60 sites in United States, Belarus and 14 more
- Volunteers
- 484 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
- Trial name
- NCT01892722
- Testing
- Interferon beta-1a, Fingolimod
- Where
- 73 sites in United States, Australia and 23 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
- Trial name
- NCT00375401
- Testing
- CP-945,598 Treatment A, CP-945,598 Treatment B
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,536 people
- Sponsor
- Pfizer
Typ 2 Diabetes, Obesity
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity
Approval study Trans-Duodenal Barrier The goal of this clinical trial is to determin the safety and performance of the newly developed Trans-Duodenal Barrier in adult Tryp 2 diabetic and obese patients.
- Conditions
- Typ 2 Diabetes, Obesity, Obesity Type 2 Diabetes Mellitus, MASH
- Trial name
- LuST (NCT07417683)
- Testing
- endoscopic implant
- Where
- 8 sites in Germany
- Volunteers
- 126 people
- Sponsor
- Trans-Duodenal Concepts GmbH
Obesity, Diabetes Mellitus Type 2
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise
The primary objective of this study is to assess the efficacy of Rimonabant (SR141716) compared to placebo on change in HbA1c and on relative change in body weight over 36 weeks in obese type 2 diabetic patients inadequately…
- Trial name
- SOLO (NCT00478972)
- Testing
- Rimonabant, Diet and exercise
- Where
- Japan
- Volunteers
- 321 people
- Sponsor
- Sanofi
Schizophrenia
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.
- Trial name
- CRESSOB (NCT00584519)
- Testing
- non-interventional
- Volunteers
- 430 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overweight or Obesity
Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects
To assess the efficacy of HRS9531 injection compared with placebo in weight reduction in overweight or obese subjects after 36 weeks of treatment.
- Trial name
- NCT06054698
- Testing
- HRS9531 injection
- Where
- 4 sites in China
- Volunteers
- 61 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Cigarette Smoking, Overweight
Comparative Effectiveness of Adding Weight Control to Smoking Cessation Quitlines
This randomized controlled trial compares the effectiveness for both smoking cessation and weight control of two alternative combined interventions offered via telephone quitline, as compared to standard of care quitline…
- Conditions
- Cigarette Smoking, Overweight, Obesity
- Trial name
- NCT01867983
- Testing
- Weight gain prevention and smoking cessation, Smoking cessation
- Where
- United States
- Volunteers
- 2,540 people, healthy volunteers welcome
- Sponsor
- Consumer Wellness Solutions